West Cancer Center

ENDOMETRIAL: METASTATIC: PHASE 1: 2nd/3rd LINE: MK-5890-001-ARM2B/C

A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Title

Merck MK-5890-001 (ENDOMETRIAL PHASE 1)

Study Title

A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Site Link

NCT03396445

Malignancy

Uterine, Endometrial

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

2nd or 3rd line

Investigational Agent

MK-5890

Drug Class

CD27 agonist

Dan Vaena, MD

Sponsor

Merck Sharp & Dohme Corp

Phase

Phase 1

Status

Closed to Accrual

Key Eligibility Criteria

Key Eligibility Criteria Details

Must have diagnosis of endometrial cancer
Must have received or been intolerant to no more than 2 prior lines of treatment
Prior treatment should have included platinum containing regimen
May be PD1 refractory (number capped)
ECOG PS 0-1
No 2nd malignancy within 2 years
No active CNS involvement
No history of interstitial lung disease
No active pneumonitis or history of non-infectious pneumonitis that required steroids
No active autoimmune disease that required systemic tx in past 2 years (other than replacement therapy)
No known HIV, HBV, HCV
No need for steroids at dose of greater than 10mg prednisone or equivalent daily
No recent history of substance abuse

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Dosing Frequency

Control Agents

Study Protocol

Randomized